2. Search Result
Search Result
Results for "

neutral endopeptidase (NEP)

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

2

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

4

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19649
    Candoxatril

    UK 79300

    		 Neprilysin Metabolic Disease
    Candoxatril is a neutral endopeptidase (NEP) inhibitor.
    Candoxatril
  • HY-17399
    Racecadotril
    3 Publications Verification

    Acetorphan

    		 Neprilysin Metabolic Disease
    Racecadotril (Acetorphan) is a neutral endopeptidase (NEP) inhibitor. Racecadotril and its active metabolite Thiorphan inhibits purified NEP activity from mouse brain with Kis of 4500 and 6.1 nM, , respectively. Antidiarrheal agent .
    Racecadotril
  • HY-19200
    RB-105

    		Neprilysin Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    RB-105 is an inhibitor of angiotensin-converting enzyme (ACE) (Ki = 4.2 nM) and neutral endopeptidase (NEP) (Ki = 1.7 nM). RB-105 after inhibiting ACE reduces the production of Ang II and increase the level of bradykinin. RB-105 after inhibiting NEP increases the level of natriuretic peptide and further increases the level of bradykinin, thereby generating a powerful synergistic effect. RB-105 has significant antihypertensive and natriuretic effects in both spontaneously hypertensive rats and normal blood pressure rats. RB-105 can be used for research on hypertension .
    RB-105
  • HY-U00294
    NEP-In-1

    		Neprilysin Neurological Disease
    NEP-IN-1 is a neutral endopeptidase (NEP) inhibitor with IC50 of 2 nM for dNEP.
    NEP-In-1
  • HY-U00336
    NEP-IN-2

    		Neprilysin Cardiovascular Disease
    NEP-IN-2 is an inhibitor of neutral endopeptidase, used in the research of proliferation in atherosclerosis, restenosis.
    NEP-IN-2
  • HY-U00171
    SQ28603

    SQ28,603; Squibb 28603

    		 Neprilysin Metabolic Disease
    SQ28603 is a potent and selective inhibitor of neutral endopeptidase 3.4.24.11 (NEP), an enzyme that degrades atrial natriuretic peptide (ANP).
    SQ28603
  • HY-123782
    (Rac)-UK-414495

    		Neprilysin Metabolic Disease
    (Rac)-UK-414495 (example 7) is a potent neutral endopeptidase (NEP) inhibitor. (Rac)-UK-414495 causes potentiation of cAMP in the sexual genitalia of the female .
    (Rac)-UK-414495
  • HY-17399S
    Racecadotril-d5

    Acetorphan-d5

    		 Isotope-Labeled Compounds Neprilysin Metabolic Disease
    Racecadotril-d5 is the deuterium labeled Racecadotril. Racecadotril (Acetorphan) is a neutral endopeptidase (NEP) inhibitor. Racecadotril and its active metabolite Thiorphan inhibits purified NEP activity from mouse brain with Kis of 4500 and 6.1 nM, , respectively. Antidiarrheal agent .
    Racecadotril-d5
  • HY-17399R
    Racecadotril (Standard)

    Acetorphan (Standard)

    		 Reference Standards Neprilysin Metabolic Disease
    Racecadotril (Standard) is the analytical standard of Racecadotril. This product is intended for research and analytical applications. Racecadotril (Acetorphan) is a neutral endopeptidase (NEP) inhibitor. Racecadotril and its active metabolite Thiorphan inhibits purified NEP activity from mouse brain with Kis of 4500 and 6.1 nM, , respectively. Antidiarrheal agent .
    Racecadotril (Standard)
  • HY-114941
    Aladotril

    BP1137

    		 Angiotensin-converting Enzyme (ACE) Neprilysin Cardiovascular Disease
    Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial infarction .
    Aladotril
  • HY-N2021
    Phosphoramidon

    		MMP Angiotensin-converting Enzyme (ACE) Neprilysin Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Phosphoramidon, a microbial metabolite, is a specific metalloprotease thermolysin inhibitor with an IC50 of 0.4 μg/mL. Phosphoramidon also inhibits endothelin-converting enzyme (ECE), neutral endopeptidase (NEP), and angiotensin-converting enzyme (ACE) with IC50 values of 3.5, 0.034, and 78 μM, respectively .
    Phosphoramidon
  • HY-106975
    SCH-42354

    		Neprilysin Cardiovascular Disease
    SCH-42354 is a potent, orally active neutral endopeptidase (NEP) inhibitor, is the pharmacologically active form of the proagent SCH-42495. SCH-42354 inhibits the hydrolysis of NEP to enhance the activity of atrial natriuretic peptide (ANP). SCH-42354 inhibits hydrolysis of leu-enkephalin and ANF with IC50 values of 8.3 nM and 10.0 nM, respectively. SCH-42354 has antihypertensive activity .
    SCH-42354
  • HY-107762
    CGS35066

    		Endothelin-Converting Enzyme (ECE) Cardiovascular Disease
    CGS35066 is a potent and selective aminophosphonate inhibitor of endothelin-converting enzyme-1 (ECE-1). CGS 35066 inhibits the activity of human ECE-1 and rat kidney neutral endopeptidase 24.11 (NEP) in vitro with IC50 values of 22 nM and 2.3 μM, respectively .
    CGS35066
  • HY-N2021A
    Phosphoramidon disodium

    		MMP Angiotensin-converting Enzyme (ACE) Neprilysin Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Phosphoramidon disodium, a microbial metabolite, is a specific metalloprotease thermolysin inhibitor with an IC50 of 0.4 μg/mL. Phosphoramidon disodium also inhibits endothelin-converting enzyme (ECE), neutral endopeptidase (NEP), and angiotensin-converting enzyme (ACE) with IC50 values of 3.5, 0.034, and 78 μM, respectively .
    Phosphoramidon disodium
  • HY-105319
    CGS-30440

    		Neprilysin Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    CGS-30440 is a potent and orally active dual inhibitor of neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE). CGS-30440 exhibit antihypertensive and natriuretic effects. CGS-30440 also shows protective effect for chronic renal failure. CGS-30440 can be used for the research of cardiovascular disease, such as hypertension .
    CGS-30440
  • HY-171461
    CGS 24592

    		Prolyl Endopeptidase (PREP) Cardiovascular Disease
    CGS 24592 is an orally active, selective and potent neutral endopeptidase 24.11 (NEP) inhibitor with an IC50 value of 1.6 nmol/L. CGS 24592 reduces the degradation of atrial natriuretic peptide (ANP), increases the concentration of ANP in the plasma, and reduces blood pressure. CGS 24592 is promising for research of cardiovascular disease, such as hypertension and congestive heart failure .
    CGS 24592
  • HY-105351
    CGS25155

    		Neprilysin Cardiovascular Disease
    CGS25155 is an orally active neutral endopeptidase 24.11 (NEP 24.11) inhibitor with an IC50 of 3 nM. CGS25155 can slow down the degradation of the cardiac hormone atrial natriuretic peptide (ANP) and exhibits antihypertensive activity in the DOCA-salt induced rat hypertension model. CGS25155 can be used in cardiovascular disease research .
    CGS25155
  • HY-123348
    Sampatrilat

    UK-81252

    		 Angiotensin-converting Enzyme (ACE) Neprilysin Cardiovascular Disease Inflammation/Immunology
    Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation .
    Sampatrilat
  • HY-P3101
    GLP-1(28-36)amide

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .
    GLP-1(28-36)amide
  • HY-18211
    CGS 35601

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    CGS 35601 is the inhibitor for endothelin-converting enzyme-1 (ECE-1), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE), with IC50s of 55, 2, and 22 nM, respectively. CGS 35601 suppresses the big endothelin-1 (big ET-1)- and angiotensin I-induced pressor response, and enhances circulation of atrial natriuretic peptide (ANP), regulates the cardiovascular function in SD rats .
    CGS 35601
  • HY-P3101A
    GLP-1(28-36)amide TFA

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .
    GLP-1(28-36)amide TFA
  • HY-118264
    MDL-100240

    		Angiotensin-converting Enzyme (ACE) Neprilysin Cardiovascular Disease
    MDL-100240 is a dual-acting angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. MDL-100240 can significantly lower blood pressure, reverse left ventricular hypertrophy, and effectively prevent hypertrophy and dilatation of the aorta and resistance arteries, with an effect comparable to that of ramipril (HY-B0279). In addition, MDL-100240 can also reduce aldosterone levels, but has no significant effect on atrial natriuretic peptide and cGMP. In 3-month-old transgenic rats, MDL-100240 can reduce adrenomedullin concentrations, prevent and reverse severe hypertension and cardiovascular damage, and enhance bradykinin effects.
    MDL-100240

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: